Novel Form of Extended-Release Gabapentin Improves Fibromyalgia Patients’ Pain Symptoms and Sleep Disorder

Novel Form of Extended-Release Gabapentin Improves Fibromyalgia Patients’ Pain Symptoms and Sleep Disorder
In a new study entitled “The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study” researchers showed that administration of the drug gabapentin (in an extended-release approach), initially prescribed as an anti-epilepsy medication, relieved fibromyalgia-associated pain symptoms and improved fibromyalgia patients' quality of life. The study was published in the journal Pain Practice. Fibromyalgia (FM) is a condition characterized by chronic widespread pain and a heightened and painful response to pressure. It is a disabling condition affecting approximately 2% of the United States population, with a higher prevalence among females. Previous studies reported that an anti-epilepsy medication – Gabapentin (gabapentin immediate release [G-IR]) – is efficient to relief FM pain (reported decreases of 30 to 40%). However, despite its efficacy and safety, G-IR has a short half-life (i.e., the amount of time required for a compound to fall to half of its initial value) and there is a need for frequent dosing. Currently, it was developed a new extended-release formulation of gabapentin – G-GR (gastroretentive gabapentin) – based on a gastric retention strategy to promote a steady release of gabapentin during its time in the stomach (approximately 10 hours before being broken down into a healthy dietary fiber). In this study, authors investigated the efficacy of G-GR to manage FM pain usin
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *